Botulinum toxin treatment of spastic equinus in cerebral palsy -: A Randomized trial comparing two injection sites

被引:25
作者
Sätilä, H
Iisalo, T
Pietikäinen, T
Seppänen, R
Salo, M
Koivikko, M
Autti-Rämö, I
Haataja, R
机构
[1] Cent Hosp Kanta Hame, Pediat Neurol Unit, SF-13530 Hameenlinna, Finland
[2] Cent Hosp Kanta Hame, Dept Physiat, SF-13530 Hameenlinna, Finland
[3] Tampere Univ Hosp, Dept Paediat Neurol, Tampere, Finland
[4] Tampere Univ Hosp, Dept Physiat, Tampere, Finland
[5] Hosp Children & Adolescents, Paediat Neurol Unit, Helsinki, Finland
[6] STAKES, Finnish Off Hlth Care Technol Assessment, Helsinki, Finland
[7] Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland
关键词
botulinum toxin type A; cerebral palsy; spastic equinus; injection site;
D O I
10.1097/01.PHM.0000160006.51859.AE
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Objective: To explore the clinical relevance of injection site by comparing two different injection techniques in children with cerebral palsy who have spastic equinus gait. Design: A total of 19 children (13 boys, 6 girls; range, 1 yr 6 mos to 7 yrs; nine hemiplegics, eight diplegics, two quadriplegics; levels I to IV with the Gross Motor Function Classification System) participated in the study. The children were randomized into two groups: the proximal group received a botulinum toxin A injection into the proximal part of both heads of the gastrocnemius, and the distal group received a botulinum toxin A injection into the mid-belly of the muscle bulks. A single-point injection of BOTOX, 3 units/kg per site, was used. Assessments of active and passive range of motion, dynamic muscle length (modified Tardieu scale), calf tone (modified Ashworth scale), and video gait analysis (Observational Gait Scale) were performed before treatment and 3, 8, and 16 wks posttreatment. Results: Active and passive dorsiflexion and calf tone in both groups and Observational Gait Scale total scores in the distal group improved at all time points. The median change from baseline values in Observational Gait Scale initial foot contact and total scores at 8 wks showed a significant difference favoring the distal group, but the clinical relevance remained tenuous. Conclusions: Using the methods described, no major changes in main outcome measures were associated with changing the injection site.
引用
收藏
页码:355 / 365
页数:11
相关论文
共 30 条
[1]   INTERRATER RELIABILITY OF A MODIFIED ASHWORTH SCALE OF MUSCLE SPASTICITY [J].
BOHANNON, RW ;
SMITH, MB .
PHYSICAL THERAPY, 1987, 67 (02) :206-207
[2]   HISTOLOGIC ASSESSMENT OF DOSE-RELATED DIFFUSION AND MUSCLE-FIBER RESPONSE AFTER THERAPEUTIC BOTULINUM-A TOXIN INJECTIONS [J].
BORODIC, GE ;
FERRANTE, R ;
PEARCE, LB ;
SMITH, K .
MOVEMENT DISORDERS, 1994, 9 (01) :31-39
[3]   BOTULINUM A TOXIN FOR THE TREATMENT OF SPASMODIC TORTICOLLIS - DYSPHAGIA AND REGIONAL TOXIN SPREAD [J].
BORODIC, GE ;
JOSEPH, M ;
FAY, L ;
COZZOLINO, D ;
FERRANTE, RJ .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1990, 12 (05) :392-399
[4]   Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment [J].
Bottos, M ;
Benedetti, MG ;
Salucci, P ;
Gasparroni, V ;
Giannini, S .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2003, 45 (11) :758-762
[5]  
Boyd R, 1997, EUR J NEUROL, V4, pS15
[6]   Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy [J].
Boyd, RN ;
Pliatsios, V ;
Starr, R ;
Wolfe, R ;
Graham, HK .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2000, 42 (01) :32-41
[7]   Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy [J].
Boyd, RN ;
Graham, HK .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 :S23-S35
[8]   Comparison of two injection techniques using botulinum toxin in spastic hemiplegia [J].
Childers, MK ;
Stacy, M ;
Cooke, DL ;
Stonnington, HH .
AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 1996, 75 (06) :462-469
[9]  
Childers MK, 1998, MUSCLE NERVE, V21, P653, DOI 10.1002/(SICI)1097-4598(199805)21:5<653::AID-MUS15>3.0.CO
[10]  
2-W